Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The key shift in the BioXcel Therapeutics story right now ...

Within the last quarter, BioXcel Therapeutics (NASDAQ:BTAI) has observed the following analyst ratings: In the last 3 months, 6 analysts have offered 12-month price targets for BioXcel Therapeutics.

The monster sell-off occurred last Thursday, after BioXcel released the results from a phase 3 clinical trial of its BXCL501, a therapy that targets the agitation suffered by Alzheimer's disease ...

Detailed price information for Bioxcel Therapeutics Inc (BTAI-Q) from The Globe and Mail including charting and trades.

Aug 27 (Reuters) - BioXcel Therapeutics (BTAI.O), opens new tab said on Wednesday it plans to seek expanded approval early next year for use of its agitation drug at home after it succeeded in a ...

Aug 14 (Reuters) - BioXcel Therapeutics Inc (BTAI.O), opens new tab said on Monday it will cut more than half of its workforce, as the drugmaker shifts its focus towards developing its agitation ...

BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares are trading higher. The AI biopharmaceutical company on Monday announced positive meeting comments from the U.S. Food and Drug Administration (FDA). What ...

BioXcel Therapeutics Inc. company facts, information and financial ratios from MarketWatch.